Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001873121 | SCV002140572 | uncertain significance | Peroxisome biogenesis disorder 2B | 2022-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with threonine, which is neutral and polar, at codon 461 of the PEX5 protein (p.Ser461Thr). This variant is present in population databases (rs369698308, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PEX5-related conditions. ClinVar contains an entry for this variant (Variation ID: 1372623). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002551152 | SCV003712690 | uncertain significance | Inborn genetic diseases | 2022-07-12 | criteria provided, single submitter | clinical testing | The c.1381T>A (p.S461T) alteration is located in exon 13 (coding exon 12) of the PEX5 gene. This alteration results from a T to A substitution at nucleotide position 1381, causing the serine (S) at amino acid position 461 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004749758 | SCV005363236 | uncertain significance | PEX5-related disorder | 2024-07-31 | no assertion criteria provided | clinical testing | The PEX5 c.1381T>A variant is predicted to result in the amino acid substitution p.Ser461Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.013% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |